205 related articles for article (PubMed ID: 25458534)
1. Role of CB2 receptors and cGMP pathway on the cannabinoid-dependent antiepileptic effects in an in vivo model of partial epilepsy.
Rizzo V; Carletti F; Gambino G; Schiera G; Cannizzaro C; Ferraro G; Sardo P
Epilepsy Res; 2014 Dec; 108(10):1711-8. PubMed ID: 25458534
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid and nitric oxide signaling interplay in the modulation of hippocampal hyperexcitability: Study on electrophysiological and behavioral models of temporal lobe epilepsy in the rat.
Carletti F; Gambino G; Rizzo V; Ferraro G; Sardo P
Neuroscience; 2015 Sep; 303():149-59. PubMed ID: 26135674
[TBL] [Abstract][Full Text] [Related]
3. Involvement of TRPV1 channels in the activity of the cannabinoid WIN 55,212-2 in an acute rat model of temporal lobe epilepsy.
Carletti F; Gambino G; Rizzo V; Ferraro G; Sardo P
Epilepsy Res; 2016 May; 122():56-65. PubMed ID: 26970948
[TBL] [Abstract][Full Text] [Related]
4. Evidences of cannabinoids-induced modulation of paroxysmal events in an experimental model of partial epilepsy in the rat.
Rizzo V; Ferraro G; Carletti F; Lonobile G; Cannizzaro C; Sardo P
Neurosci Lett; 2009 Sep; 462(2):135-9. PubMed ID: 19595742
[TBL] [Abstract][Full Text] [Related]
5. WIN55212-2 attenuates amyloid-beta-induced neuroinflammation in rats through activation of cannabinoid receptors and PPAR-γ pathway.
Fakhfouri G; Ahmadiani A; Rahimian R; Grolla AA; Moradi F; Haeri A
Neuropharmacology; 2012 Sep; 63(4):653-66. PubMed ID: 22634229
[TBL] [Abstract][Full Text] [Related]
6. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
7. R-(+)-[2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)-pyrrolo-[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphtalenylmethanone (WIN-2) ameliorates experimental autoimmune encephalomyelitis and induces encephalitogenic T cell apoptosis: partial involvement of the CB(2) receptor.
Sánchez AJ; González-Pérez P; Galve-Roperh I; García-Merino A
Biochem Pharmacol; 2006 Dec; 72(12):1697-706. PubMed ID: 17007821
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of spontaneous neurotransmission in the nucleus of solitary tract of the rat by the cannabinoid agonist WIN 55212-2 is not via CB1 or CB2 receptors.
Accorsi-Mendonça D; Almado CE; Dagostin AL; Machado BH; Leão RM
Brain Res; 2008 Mar; 1200():1-9. PubMed ID: 18308297
[TBL] [Abstract][Full Text] [Related]
9. Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating Delta9-tetrahydrocannabinol.
McMahon LR
J Pharmacol Exp Ther; 2006 Dec; 319(3):1211-8. PubMed ID: 16943255
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid CB(2) receptor activation prevents bronchoconstriction and airway oedema in a model of gastro-oesophageal reflux.
Cui YY; D'Agostino B; Risse PA; Marrocco G; Naline E; Zhang Y; Chen HZ; Finance O; Rinaldi-Carmona M; Rossi F; Advenier C
Eur J Pharmacol; 2007 Nov; 573(1-3):206-13. PubMed ID: 17643417
[TBL] [Abstract][Full Text] [Related]
11. The cannabinoid agonist WIN 55,212-2 inhibits TNF-alpha-induced neutrophil transmigration across ECV304 cells.
Nilsson O; Fowler CJ; Jacobsson SO
Eur J Pharmacol; 2006 Oct; 547(1-3):165-73. PubMed ID: 16928371
[TBL] [Abstract][Full Text] [Related]
12. Anandamide-mediated CB1/CB2 cannabinoid receptor--independent nitric oxide production in rabbit aortic endothelial cells.
McCollum L; Howlett AC; Mukhopadhyay S
J Pharmacol Exp Ther; 2007 Jun; 321(3):930-7. PubMed ID: 17379772
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid/agonist WIN 55,212-2 reduces cardiac ischaemia–reperfusion injury in Zucker diabetic fatty rats: role of CB2 receptors and iNOS/eNOS.
González C; Herradón E; Abalo R; Vera G; Pérez-Nievas BG; Leza JC; Martín MI; López-Miranda V
Diabetes Metab Res Rev; 2011 May; 27(4):331-40. PubMed ID: 21309057
[TBL] [Abstract][Full Text] [Related]
14. Diuretic effects of cannabinoids.
Paronis CA; Thakur GA; Bajaj S; Nikas SP; Vemuri VK; Makriyannis A; Bergman J
J Pharmacol Exp Ther; 2013 Jan; 344(1):8-14. PubMed ID: 23019138
[TBL] [Abstract][Full Text] [Related]
15. Neurochemical evidence that stimulation of CB1 cannabinoid receptors on GABAergic nerve terminals activates the dopaminergic reward system by increasing dopamine release in the rat nucleus accumbens.
Sperlágh B; Windisch K; Andó RD; Sylvester Vizi E
Neurochem Int; 2009 Jun; 54(7):452-7. PubMed ID: 19428788
[TBL] [Abstract][Full Text] [Related]
16. Suppression of outward K⁺ currents by WIN55212-2 in rat retinal ganglion cells is independent of CB1/CB2 receptors.
Zhang CQ; Wu HJ; Wang SY; Yin S; Lu XJ; Miao Y; Wang XH; Yang XL; Wang Z
Neuroscience; 2013 Dec; 253():183-93. PubMed ID: 24013008
[TBL] [Abstract][Full Text] [Related]
17. Neuronal nitric oxide synthase is involved in CB/TRPV1 signalling: Focus on control of hippocampal hyperexcitability.
Carletti F; Gambino G; Rizzo V; Ferraro G; Sardo P
Epilepsy Res; 2017 Dec; 138():18-25. PubMed ID: 29035821
[TBL] [Abstract][Full Text] [Related]
18. The CB1/CB2 receptor agonist WIN-55,212-2 reduces viability of human Kaposi's sarcoma cells in vitro.
Luca T; Di Benedetto G; Scuderi MR; Palumbo M; Clementi S; Bernardini R; Cantarella G
Eur J Pharmacol; 2009 Aug; 616(1-3):16-21. PubMed ID: 19539619
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats.
Zaniewska M; McCreary AC; Przegaliński E; Filip M
Eur J Pharmacol; 2006 Jul; 540(1-3):96-106. PubMed ID: 16730696
[TBL] [Abstract][Full Text] [Related]
20. The cannabinoid antagonist SR144528 enhances the acute effect of WIN 55,212-2 on gastrointestinal motility in the rat.
Abalo R; Cabezos PA; Vera G; Fernández-Pujol R; Martín MI
Neurogastroenterol Motil; 2010 Jun; 22(6):694-e206. PubMed ID: 20132133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
